SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S44 - MS Risk Factors and Modifications

Event Time: Thursday April 27, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:05 PM - 5:30 PM Discussion Kassandra Munger  

Disclosures

Speaker Disclosure
Kassandra L. Munger Dr. Munger has nothing to disclose.

Abstract Presenters

Start Time Pub. Title Presenter
3:30 PM 001 The effect of hospitalization on subsequent disability in multiple sclerosis Ruth-Ann Marrie, MD
Disclosure:
Dr. Marrie has nothing to disclose.

3:42 PM 002 A survey of current dietary habits within a large population of people with multiple sclerosis Kathryn C. Fitzgerald
Disclosure:
Dr. Fitzgerald has nothing to disclose.

3:54 PM 003 Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited. Shayandokht Taleb, MD
Disclosure:
Dr. Taleb has nothing to disclose.

4:06 PM 004 Cholecalciferol supplementation in Relapsing Multiple Sclerosis patients treated with subcutaneous interferon beta-1a: a Randomized Controlled Trial. William Camu, MD
Disclosure:
Dr. Camu has received personal compensation for activities with Actelion, Biogen-Idec, Merck Serono, Novartis and Sanofi in the form of honoraria or research grants.

4:18 PM 005 High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon 1a (scIFN?-1a) Raymond Hupperts
Disclosure:
Dr. Smolders has nothing to disclose.

4:30 PM 006 Maternal levels of Epstein-Barr virus IgG antibodies and risk of multiple sclerosis in offspring in the Finnish Maternity Cohort Kassandra Munger
Disclosure:
Dr. Munger has nothing to disclose.

4:42 PM 007 Epstein-Barr virus, Cytomegalovirus, the Hygeine Hypothesis and Multiple Sclerosis Susceptibility: A Multi-Ethnic Study Annette Langer-Gould, MD, PhD
Disclosure:
Dr. Langer-Gould has received research support from Biogen Idec, Inc.

4:54 PM 008 Familial Transverse Myelitis Associated with Mutation in VPS37A Gene Santiago Pardo
Disclosure:
Dr. Pardo has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?